ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
(technical difficulty) joining us. I am Tazeen Ahmad, I'm the Senior SMid Biotech analyst of Bank of America Merrill Lynch. Welcome to our Healthcare Conference. It's my pleasure to introduce the next presenting company, ACADIA Pharmaceuticals. With us from ACADIA at the podium is Steve Davis, CEO. Sitting next to me is Elena Ridloff, CFO of the company. And in the audience, we have Mark Johnson from IR. Steve's going to start off with a couple of slides just giving you an introduction to the company and what the company is focused on, and then we'll switch to Q&A right after that.
So with that, I'll turn it over to Steve.
Great. Thanks much, Tazeen, and good morning to each of you. I need to start just reminding all of us that the business of pharmaceutical development and commercialization has certain risks inherent in the business. Please see a copy of our most recent SEC filings for a description of risks that relate our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |